As of the latest Form 4 filed Jul 9, 2026.
What Neurocrine Biosciences Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 37 most recent filings for NBIX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-09 | 2026-07-09 | Delaet Ingrid Chief Regulatory Officer | SSale | −8.43K | $178.72 | $1.51M | Yes (planned) | Form 4 ↗ |
| 2026-07-09 | 2026-07-09 | Delaet Ingrid, Chief Regulatory Officer | MExercise | +8.43K | $103.52 | $873K | Yes (planned) | Form 4 ↗ |
| 2026-07-09 | 2026-07-08 | Delaet Ingrid, Chief Regulatory Officer | SSale | −2.74K | $178.54 | $489K | Yes (planned) | Form 4 ↗ |
| 2026-07-09 | 2026-07-08 | Delaet Ingrid, Chief Regulatory Officer | MExercise | +2.74K | $103.52 | $283K | Yes (planned) | Form 4 ↗ |
| 2026-07-09 | 2026-07-07 | Delaet Ingrid, Chief Regulatory Officer | SSale | −3.40K | $178.57 | $607K | Yes (planned) | Form 4 ↗ |
| 2026-07-09 | 2026-07-07 | Delaet Ingrid, Chief Regulatory Officer | MExercise | +3.40K | $103.52 | $352K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | Lippoldt Darin Chief Legal Officer | SSale | −1.69K | $170.81 | $289K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | Lippoldt Darin, Chief Legal Officer | MExercise | +1.69K | $81.49 | $138K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | Lippoldt Darin, Chief Legal Officer | SSale | −8.11K | $170.03 | $1.38M | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | Lippoldt Darin, Chief Legal Officer | MExercise | +8.11K | $81.49 | $661K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | Lippoldt Darin, Chief Legal Officer | SSale | −200.00 | $169.57 | $33.9K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | Lippoldt Darin, Chief Legal Officer | MExercise | +200.00 | $81.49 | $16.3K | Yes (planned) | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | Onyia Jude Chief Scientific Officer | GGift | −2.44K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | SHERWIN STEPHEN A Director | SSale | −1.84K | $167.31 | $308K | Yes (planned) | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | SHERWIN STEPHEN A, Director | SSale | −5.83K | $166.56 | $971K | Yes (planned) | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | SHERWIN STEPHEN A, Director | SSale | −6.90K | $165.79 | $1.14M | Yes (planned) | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | SHERWIN STEPHEN A, Director | SSale | −2.55K | $164.44 | $419K | Yes (planned) | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | SHERWIN STEPHEN A, Director | SSale | −7.88K | $163.81 | $1.29M | Yes (planned) | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | SHERWIN STEPHEN A, Director | MExercise | +10.0K | $79.79 | $798K | Yes (planned) | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | SHERWIN STEPHEN A, Director | MExercise | +15.0K | $53.64 | $805K | Yes (planned) | Form 4 ↗ |
| 2026-06-08 | 2026-06-04 | Norwalk Leslie V Director | SSale | −1.25K | $168.06 | $210K | Yes (planned) | Form 4 ↗ |
| 2026-06-04 | 2026-06-02 | Keswani Sanjay Chandru Chief Medical Officer | FTax | −1.73K | $154.84 | $268K | No | Form 4 ↗ |
| 2026-06-04 | 2026-06-02 | Keswani Sanjay Chandru, Chief Medical Officer | MExercise | +3.21K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-04 | 2026-06-02 | Cooke Julie Chief Human Resources Officer | SSale | −3.52K | $158.59 | $558K | Yes (planned) | Form 4 ↗ |
| 2026-06-04 | 2026-06-02 | Cooke Julie, Chief Human Resources Officer | SSale | −9.52K | $157.62 | $1.50M | Yes (planned) | Form 4 ↗ |
| 2026-06-04 | 2026-06-02 | Cooke Julie, Chief Human Resources Officer | SSale | −4.22K | $156.77 | $661K | Yes (planned) | Form 4 ↗ |
| 2026-06-04 | 2026-06-02 | Cooke Julie, Chief Human Resources Officer | SSale | −5.47K | $155.46 | $850K | Yes (planned) | Form 4 ↗ |
| 2026-06-04 | 2026-06-02 | Cooke Julie, Chief Human Resources Officer | SSale | −14.2K | $154.83 | $2.20M | Yes (planned) | Form 4 ↗ |
| 2026-06-04 | 2026-06-02 | Cooke Julie, Chief Human Resources Officer | MExercise | +25.0K | $81.49 | $2.03M | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Onyia Jude Chief Scientific Officer | SSale | −11.0K | $160.25 | $1.76M | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Onyia Jude, Chief Scientific Officer | MExercise | +11.0K | $84.74 | $932K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-05-29 | Delaet Ingrid Chief Regulatory Officer | SSale | −2.26K | $156.71 | $354K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-05-29 | Delaet Ingrid, Chief Regulatory Officer | MExercise | +2.26K | $79.02 | $179K | Yes (planned) | Form 4 ↗ |
| 2026-05-29 | 2026-05-27 | Onyia Jude Chief Scientific Officer | SSale | −11.0K | $155.53 | $1.71M | Yes (planned) | Form 4 ↗ |
| 2026-05-29 | 2026-05-27 | Onyia Jude, Chief Scientific Officer | MExercise | +11.0K | $84.74 | $932K | Yes (planned) | Form 4 ↗ |
| 2026-05-28 | 2026-05-26 | Boyer David W. Chief Corp. Affairs Officer | SSale | −3.89K | $156.64 | $609K | Yes (planned) | Form 4 ↗ |
| 2026-05-14 | 2026-05-12 | Norwalk Leslie V Director | SSale | −3.81K | $155.01 | $591K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also NBIX’s full analysis or the market-wide insider trading feed. The tabs above jump to NBIX’s other SEC data.
Source: SEC Form 4 filings for NBIX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.